Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis
Annals of Rheumatic Diseases,  Clinical Article

Papadopoulou A et al. – Mesenchymal stem cells (MSC) lose their immunomodulatory properties when infused in the inflammatory micromilieu of autoimmune arthritis. Conditioning of the recipient with bortezomib alters the disease microenvironment enabling MSC to modulate arthritis. Should milieu limitations also operate in human disease, this approach could serve as a strategy to treat rheumatoid arthritis (RA) by MSC.

Methods
  • MSC were tested both in an induced (adjuvant–induced) and a spontaneous (K/BxN) arthritis model. Arthritis was assessed clinically and histologically.
  • The proliferation of splenocytes and fibroblast–like synoviocytes (FLS) in the presence of MSC was measured by radioactivity incorporation.
  • Toll–like receptor (TLR) expression was measured by real–time PCR. T–regulatory cell (Treg) frequency, T–cell apoptosis and cytokine secretion were monitored by flow cytometry.

Results
  • MSC, in vitro, strongly inhibited critical cell populations; splenocytes and FLS.
  • In contrast, MSC proved ineffective in vivo, unless they were administered before disease onset, an effect implying that the inflammatory arthritic milieu potentially abrogates MSC immunomodulatory properties.
  • In order to alleviate inflammation before MSC infusion, the authors administered, at arthritis onset, a short course with a proteasome inhibitor, bortezomib, whereas MSC were infused when established disease was expected.
  • The bortezomib plus MSC group demonstrated a significantly decreased arthritis score over arthritic, MSC–only, bortezomib–only groups, also confirmed by histology and immunohistochemistry.
  • The bortezomib plus MSC combination restored TLR expression and Treg frequency in blood and normalised FLS and splenocyte proliferation, apoptosis and cytokine secretion.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

2 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

3 Homeopathy in the treatment of fibromyalgia- A comprehensive literature-review and meta-analysis Complementary Therapies in Medicine, August 15, 2014    Evidence Based Medicine    Review Article

4 Blood test could prevent medication trial and error for rheumatoid arthritis patients Mayo Clinic, November 18, 2014

5 Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: The TRIO study Osteoporosis International, November 12, 2014    Clinical Article

6 Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial Annals of Rheumatic Diseases, November 10, 2014    Clinical Article

7 New treatments for inflammatory rheumatic disease Immunologic Research, November 17, 2014    Review Article

8 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

9 Sustained remission with etanercept tapering in early rheumatoid arthritis New England Journal of Medicine, November 10, 2014    Evidence Based Medicine    Clinical Article

10 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

11 Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: An observational cohort study Rheumatology, August 12, 2014    Clinical Article

12 Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? Immunologic Research, November 17, 2014    Review Article    Clinical Article

13 Comparison of the efficacy, adverse effects and cost of zoledronic acid and denosumab in the treatment of osteoporosis Endocrine Practice, November 7, 2014    Review Article

14 Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study Annals of Rheumatic Diseases, November 18, 2014    Clinical Article

15 A double-blind, placebo-controlled, randomized, 12-week, dose-ranging study of VX-509 (decernotinib), an oral selective janus kinase 3 (JAK3) inhibitor, as monotherapy in patients with active rheumatoid arthritis Arthritis & Rheumatism, November 14, 2014    Clinical Article

16 Yearly treatment could slow osteoarthritis Monash University News, September 23, 2014

17 Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study Clinical Rheumatology, February 17, 2014    Clinical Article

18 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study Annals of Rheumatic Diseases, August 12, 2014    Clinical Article

19 Drug-associated cutaneous vasculitis: Study of 239 patients from a single referral center The Journal of Rheumatology, September 25, 2014    Clinical Article

20 Study by UCLA scientists reveals new findings about cause of lesions around jaw bone UCLA Health System, November 26, 2014

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore